neffy 1 mg is the first approved needle-free epinephrine nasal spray for children aged 4 to 30 kg, addressing severe allergic reactions. ARS Pharmaceuticals announced the FDA approval of neffy 1 mg, ...
Qualifying public and private K-12 Schools in the U.S. will be eligible to receive two free cartons (four single use doses) of neffy ® (epinephrine nasal spray) 2mg for use in emergency treatment of ...
Visit neffy.com to “Get neffy Now” and access the comprehensive patient assistance programs available through neffyConnect ARS Pharmaceuticals has also submitted a supplemental New Drug Application ...
Credit: ARS Pharmaceuticals. Each carton contains 2 blister packages each with a single-dose nasal spray product for 1 time use. It is recommended that patients be prescribed and have immediate access ...
Neffy needle-free epinephrine spray sales surge, global expansion, and CSU Phase 2b upside. See more on SPRY here.
SAN DIEGO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves ...
Five poster presentations highlight clinical advancement of neffy , real-world usability and advantages of needle-free epinephrine ...
EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS Pharma’s partner, ALK-Abelló A/S, who owns the rights to market EURneffy in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results